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Purpose. To document subtype-specific clinical features of lymphoma of the eyelid, 
and their effect on patient outcome. 
Design. Retrospective observational case series. 
Methods. Patient data were collected from 7 international eye cancer centers from 
January 1st 1980 through December 31st 2015. The cases included primary and 
secondary lymphomas affecting the eyelid. Overall survival, disease-specific survival 
(DSS), and progression-free survival were the primary end points. 
Results. Eighty-six patients were included. Mean age was 63 years and 47 (55%) were 
male. Non-Hodgkin B-cell lymphomas constituted 83% (n=71) and T-cell lymphomas 
constituted 17% (n=15). The most common subtypes were extranodal marginal-zone 
lymphoma (EMZL) (37% [n=32]), follicular lymphoma (FL) (23% [n=20]), diffuse large B-
cell lymphoma (DLBCL) (10% [n=9]), mantle cell lymphoma (MCL) (8% [n=7]) and 
mycosis fungoides (MF) (9% [n=8]). 
EMZL had a female predilection (69% [22 of 32]), whereas MCL (71% [5 of 7]) and MF 
(88% [7 of 8]) had a male predominance. MCL (57% [4 of 7]), DLBCL (56% [5 of 9]) 
and MF (88% [7 of 8]) were frequently secondary lymphomas. Localized EMZL and FL 
were mostly treated with external beam radiation therapy, whereas DLBCL, MCL and 
high Ann Arbor stage EMZL and FL were frequently treated with chemotherapy. DLBCL 
and MCL had a poor prognosis (5-year DSS, 21% and 50%, respectively), whereas 
EMZL, FL and MF had a good prognosis (5-year DSS, 88%, 88% and 86%, 
respectively).  
Conclusions. Lymphoma of the eyelid consists mainly of the lymphoma subtypes: 
EMZL, FL, DLBCL, MCL and MF. High-grade DLBCL and MCL as well as MF are 
frequently secondary eyelid lymphomas. The main predictor of outcome was the 
histological subtype: EMZL, FL and MF had a significantly better prognosis than MCL 
and DLBCL. 
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1. Introduction 
Lymphomas are malignant neoplasms originating from clonal proliferations of 
lymphocytes and are a heterogeneous group with more than 40 subtypes.1 Lymphomas 
can occur within nodes or extranodally and originate from B-cells, T-cells or more 
seldom NK-cells. Ocular adnexal lymphomas (OAL) constitute 2% of all extranodal 
lymphomas2 and 5% of OAL are located in the eyelid.3 
 Lymphoma of the eyelid (LE) is defined as lymphoma involving the pre-septal 
tissues: the skin, subcutaneous connective tissue and orbicularis oculi muscle.4  
 LE consists of several different subtypes of B-cell, T-cell and NK-cell origin. Low-
grade B-cell lymphomas include extranodal marginal-zone lymphoma (EMZL), follicular 
lymphoma (FL) and extramedullary plasmacytoma. High-grade B-cell lymphomas 
include diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).5 The 
most common T-cell lymphoma involving the eyelid is mycosis fungoides (MF).5 The 
distribution of LE subtypes appears to be different from lymphomas in other ocular 
adnexal sites with a higher rate of eyelid T-cell lymphomas and a lower rate of eyelid 
EMZL.5  
 LE is a rare disease with 199 cases reported in the literature.5 To our knowledge, 
no large cohort studies of specific lymphoma subtypes of the eyelid have been made 
and, therefore, clinical data of LE are limited. The primary predictor for prognosis of LE 
has been found to be the histological lymphoma subtype.5 Overall LE are considered to 
have a worse prognoses than lymphomas in other ocular adnexal sites.6 This is 
incorporated into the American Joint Committee on Cancer (AJCC) staging system, 
where involvement of the eyelid, regardless of other factors, is staged as stage T3 or 
higher.4 Because of the diversity and heterogenic nature of lymphoma subtypes of the 
eyelid, analyses of the different subtypes are needed. The aim of this study was to 
describe the major subtypes of LE with their clinical features and their effect on survival 
in a cohort from 7 international eye cancer centers. 
 
2. Methods 
2.1. Study design 
In this observational case series, patients with lymphoma of the eyelid with the main 
tumor bulk involving the pre-septal tissues were included. The patients were collected 
from January 1st 1980 to December 31st 2015. The analysis of the data was 
undertaken at study closure between May 20th - August 18th 2016.  
 Specimens were first stained with hematoxylin-eosin and analyzed 
immunohistochemically with a panel of antibodies for histopathological examination. 
Current guidelines1 recommend the following panel for small cell lymphomas: CD3, 
CD5, CD10, CD20, CD23, CD79α, cyclin D-1, Bcl-2, Bcl-6, multiple myeloma oncogene 
1 (MUM-1), methylation-inhibited binding protein 1 (MIB-1), and κ and λ light-chains. 
Guidelines for large cell lymphomas are: CD3, CD5, CD10, CD20, CD30, CD79α, Bcl-
2, Bcl-6, MUM-1, and MIB-2. The data collection spans more than 30 years, and 
includes 7 eye cancer centers: Copenhagen, Denmark; Liverpool, England; Houston, 
Texas; Hyderabad, India; New York, New York, USA; Atlanta, Georgia, USA; and 
Melbourne, Australia, and therefore not all samples were analyzed in this uniform 
matter. However, the cancer centers reviewed the specimens and reclassified them 
according to the World Health Organization Classification of Tumours of Hematopoietic 
and Lymphoid tissues.1  
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 This study followed the tenets of the Declaration of Helsinki and the Health 
Insurance Portability and Accountability Act of 1996 in the United States. Institutional 
review board and health information privacy agency approvals were obtained from the 
Danish Data Protection Agency. 
 
2.2. Clinical data 
The clinical data recorded included age, gender, symptoms, clinical findings, laterality, 
systemic involvement and thus the Ann Arbor stage, the AJCC/TNM stage, treatment 
modalities, response to treatment, survival duration and cause of death. The Ann Arbor 
staging system stages lymphomas from stage I to stage IV. Stage I is lymphoma in a 
single region. Stage II is lymphoma in two separate regions on only one side of the 
diaphragm. Stage III is lymphoma spread to both sides of the diaphragm. Stage IV is 
diffusely disseminated lymphoma.  
 Involvement of lymph nodes, bone marrow or other extranodal sites was 
determined with diagnostic tools available at the time of diagnosis and clinical data. At 
present complete diagnostic work-up includes full-body PET-CT, CT or MRI of the 
eyelid and a bone marrow biopsy. 
 Primary LE was defined by the following: (1) Biopsy-proven lymphoma with no 
concurrent systemic disease at the time of diagnostic work-up, meaning lymphoma 
confined to the ocular adnexa (stage IE) with or without involvement of unilateral 
preauricular or submandibular lymph nodes or adjacent structures (stage IIE) and (2) 
no prior history of lymphoma. Consequently, secondary lymphoma is defined as 
systemic lymphoma with a secondary manifestation of the eyelid or lymphoma relapse 
affecting the eyelid on the background of clinically-known systemic lymphoma. 
 
2.3. Statistical analysis 
The primary end points considered were overall survival (OS), disease-specific survival 
(DSS) and progression-free survival (PFS). OS was defined as date of diagnosis of LE 
to death of any cause or last follow-up, with the latter being a censored event. DSS was 
defined as date of diagnosis to the date of death because of lymphoma or the date of 
last contact, the latter being a censored event. PFS was calculated from date of 
diagnosis to either the date of first relapse or progression after initial treatment, to the 
date of death of any cause or to the date of last contact, with the latter 2 being 
censored events. Life tables and Kaplan-Meier plots were made to show survival 
outcomes. Different risk factors were compared using the χ2 or Fisher’s Exact test 
depending on the number of patients. Statistical analysis and calculation were done 
using a software program (IBM SPSS Package, version 22; IBM Corporation). 
 
3. Results 
Eighty-six patients were identified with LE from the database of 7 eye cancer centers: 
Copenhagen, Denmark (n=22); Liverpool, England (n=33); Houston, Texas (n=22); 
Hyderabad, India (n=4); New York, New York, USA (n=3); Atlanta, Georgia, USA (n=1); 
and Melbourne, Australia (n=1). (Table 1) Six B-cell lymphoma subtypes were 
identified: EMZL (n=32); FL (n=20); DLBCL (n=9); MCL (n=7); lymphoplasmacytic 
lymphoma (LPL) (n=1); and small lymphocytic lymphoma (SLL/CLL) (n=1). Five T-cell 
lymphoma subtypes were identified: MF (n=8); peripheral T-cell lymphoma (PTCL) 
(n=2); lymphomatoid papulosis (LyP) (n=2); primary cutaneous anaplastic large cell 
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lymphoma (C-ALCL) (n=1); and anaplastic large cell lymphoma (ALCL) (n=1). One 
case each of a B- and a T-cell lymphoma could not be subtyped further. The median 
follow-up period was 53 months (range, 0-251 months).  
The most common symptom for all LE subtypes was a tumor and/or swelling of the 
eyelid. (Table 2) Ulceration and mechanical ectropion seem to be signs of T-cell 
lymphomas with 27% (4 of 15) of the T-cell lymphoma patients showing ulceration, and 
75% (6 of 8) of MF showing mechanical ectropion, whereas no B-cell lymphoma patient 
showed either sign. The AJCC/TNM staging system regards lymphoma with 
involvement of the pre-septal eyelid as stage T3 or higher.4 In this study all cases of 
primary LE were staged as stage T3. (Table 3) 
 
3.1. Major Non-Hodgkin B-cell Lymphoma subtypes 
3.1.1. Extranodal marginal zone lymphoma 
Clinical features. 32 patients (37%) were diagnosed with EMZL. The median age was 
63.5 years (age range, 19-90 years). Twenty-two had primary lymphoma (69%), 24 had 
stage IE disease (75%) and 24 had unilateral involvement (77% [n=24 of 31]). (Table 3) 
The median symptom duration was 7 months (range, 2-36 months). 
Treatment. The most common treatment for stage IE/IIE lymphoma was external beam 
radiation therapy (EBRT) (81% [n=21 of 26]) either alone or with chemotherapy (31% 
[n=8 of 26]). Stage IIIE/IVE lymphoma was treated with chemotherapy (67% [n=4 of 6]) 
with or without EBRT. (Table 4) The median radiation dose was 30.6 Gy (range, 26-40 
Gy). The applied chemotherapy was CVP (cyclophosphamide, vincristine and 
prednisone), rituximab and unspecified chemotherapy. 
Treatment outcome and survival. 21 patients experienced relapse (66%). The 
median duration before relapse was 35 months (range, 9-155 months). The median 
PFS was 61 months (range, 2-251 months). The OS and DSS rates at 5 years were 
86% and 88%, respectively (median survival 5.5 years; 95% CI, 3.8-7.2 years). 
 
3.1.2. Follicular lymphoma 
Clinical features. Twenty patients (23%) were diagnosed with FL. The median age 
was 60 years (age range, 41-81 years). Sixteen patients (80%) had primary LE, 15 had 
unilateral involvement (75%) and 12 had stage IE lymphoma (60%). (Table 3) The 
median symptom duration was 5 months (range, 1-36 months). 
Treatment. Stage IE/IIE disease were mostly treated with EBRT (67% [n=10 of 15]) 
with or without chemotherapy, whereas all stage IVE patients were treated with 
chemotherapy with or without EBRT. (Table 4) Median radiation dose was 30 Gy 
(range, 4-36 Gy). The chemotherapy applied consisted of CHOP (cyclophosphamide, 
hydroxydaunorubicin, vincristine and prednisone), CVP, rituximab, ibritumomab 
tiuxetan and unspecified chemotherapy. 
Treatment outcome and survival. Relapse of lymphoma was observed in 12 patients 
(60%). (Table 3) The median duration before relapse was 23 months (range, 2-72 
months). The median PFS was 49 months (range, 1-110 months). The OS rate and 
DSS rate at 5 years were 80% and 88%, respectively (median survival 5.0 years; 95% 
CI, 3.2-6.8 years). 
 
3.1.3. Diffuse large B-cell lymphoma 
Clinical features. Nine patients (10%) were diagnosed with DLBCL. The median age 
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was 61 years (age range, 29-93 years). DLBCL presented unilateral in all 9 cases and 
more than half as secondary lymphoma (56% [n=5]). (Table 3) Median symptom 
duration was 1 month (range, 1-4 months). 
Treatment. All patients were treated with chemotherapy with or without EBRT. 
Radiation dose was known in one case, who was treated with 36 Gy. Applied 
chemotherapy was CHOP, hyper-CVAD (cyclophosphamide, vincristine, 
hydroxydaunorubicin and dexamethasone), rituximab, methotrexate and unspecified 
chemotherapy. 
Treatment outcome and survival. Relapse was observed in 7 patients (78%). Median 
time to relapse was 1 month (range, 0-5 months). The median PFS was 5 months 
(range, 0-23 months). The OS at 5 years was 13%, whereas the DSS at 5 years was 
21% (median survival 1.9 years, 95% CI, 0.7-3.1 years). 
 
3.1.4. Mantle cell lymphoma 
Clinical features. Seven patients (8%) were diagnosed with MCL. Five (71%) were 
male and the median age was 75 years (age range, 67-84 years). Five patients had 
unilateral involvement (71%). (Figure 1) The median symptom duration was 7 months 
(range, 6-8 months). 
Treatment. All 7 patients were treated with chemotherapy and 5 patients (71%) were 
also treated with EBRT. Radiation dose was known in one case and was 24 Gy. The 
applied chemotherapy was CHOP, hyper-CVAD, bortezomib, methotrexate, 
antimetabolites and unspecified chemotherapy. 
Treatment outcome and survival. Recurrence of lymphoma was observed in all 7 
patients. (Table 3) The median duration before relapse was 11 months (range, 5-23 
months). Both the OS rate and DSS rate at 5 years were 50%. The median survival 
was 2.1 years (95% CI, -0.2-4.4 years). 
 
3.2. Rare Non-Hodgkin B-cell Lymphoma subtypes 
3.2.1. Lymphoplasmacytic lymphoma 
One 68-year-old female was diagnosed with primary bilateral LPL (stage IIE). She 
experienced nodal relapse and died of lymphoma after 32 months. 
 
3.2.2. Small lymphocytic lymphoma 
One 75-year-old man had relapsed bilateral SLL/CLL (stage IVE) through 9 months. He 
was treated with alkylating agents and surgery, but experienced relapse in the eyelids 
11 months later and died of other causes 93 months later. 
 
3.3. Major T-cell lymphoma subtypes 
3.3.1. Mycosis fungoides 
Clinical features. Eight patients (9%) had MF, 7 were male (88%) and the median age 
was 78 (age range, 58-88 years). Six patients (75%) had a history of prior MF and one 
had prior FL and all 8 patients had bilateral involvement. The most common symptom 
was mechanical ectropion (63% [n=5]). (Table 2) 
Treatment. Stage IE/IIE was treated with EBRT with or without chemotherapy. Stage 
IVE disease was treated with a combination of EBRT and chemotherapy. (Table 4) The 
median radiation dose was 32 Gy (range, 20-37 Gy). The applied chemotherapy 
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included topical nitrogen mustard, methotrexate, CHOP, antimetabolites and retinoid 
synthetics. 
Treatment outcome and survival. Three of 7 experienced relapse (43%). Relapse 
time was known in one patient and was 18 months. The median PFS was 31 months 
(range, 6-101 months). The OS and DSS rates at 5 years were 42% and 86%, 
respectively (median, 2.4 years; 95% CI, -0.5-5.2 years).  
 
3.4. Rare T-cell lymphoma subtypes 
3.4.1. Peripheral T-cell lymphoma 
Two male patients, aged 35 and 59 years, were diagnosed with unilateral PTCL. The 
duration of symptoms was known in one patient and was 1 month. One patient 
experienced relapse on his tongue after 66 months and the other experienced nodal 
relapse, but achieved complete remission at 26 months after diagnosis of LE. 
 
3.4.2. Lymphomatoid papulosis 
Two male patients, aged 73 and 34 years, were diagnosed with primary unilateral LyP 
(stage IE). One patient had symptom duration of one month and the treatment was only 
surgery in the other patient. They were both in complete remission at 46 and 78 
months, respectively. One patient died of non-lymphoma related disease 78 months 
after the diagnosis of LE. 
 
3.4.3. Primary cutaneous anaplastic large cell lymphoma 
A 61-year-old male had primary unilateral C-ALCL (stage IE) through one month. He 
was treated with 30 Gy and CHOP. After 6 months, the patient had relapse in the same 
eyelid, but was in complete remission 32 months later. 
 
3.4.4. Anaplastic large cell lymphoma 
One 54-year old male patient was diagnosed with disseminated ALCL (stage III) after 2 
months of symptoms. He was treated with CHOP and was in complete remission at 78 
months from the time of diagnosis. 
 
4. Discussion 
The distribution of LE subtypes had a markedly higher rate of MF, a higher rate of FL 
and a markedly lower rate of EMZL compared to other ocular adnexal sites.3,7 However, 
the spectrum of subtypes of B-cell lymphoma subtypes was the same as for other 
ocular adnexal region lymphomas,3 whereas T-cell lymphoma is very rare in other 
ocular adnexal structures.3 T-cell lymphomas have a predilection for the skin, and 
therefore T-cell lymphomas have a higher incidence in the eyelid region compared to 
the rest of the eye region. 
 LE tends to be a disease of the elderly, with a mean age of 63 years. The median 
age for EMZL (64 years), FL (60 years) and MCL (75 years) seem to follow the regular 
age pattern for other OAL.3,7-9 However, the median age for DLBCL is lower compared 
to other ocular adnexal sites (e.g. conjunctiva, 74 years7 and OAL, 70-77 years3,10 
versus LE, 61 years). T-cell lymphomas as well as MCL had a high frequency in male 
patients, whereas EMZL had a predilection for female patients. (Table 3) Ulceration and 
mechanical ectropion seem to be signs of T-cell lymphomas. We suspect that 
ulceration was the cause of some cases of mechanical ectropion. The symptom 
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duration before diagnosis was longer in low-grade lymphomas EMZL and FL (median 
duration, 8 and 5 months, respectively), than the high-grade lymphoma DLBCL (median 
duration, 1 month). The high-grade B-cell lymphomas and the T-cell lymphoma MF are 
more likely secondary than FL and EMZL. (Table 3) Orbital spread is much more 
frequent in B-cell lymphomas than T-cell lymphomas (Table 2), which has also 
previously been stated.5  
 In this study, the treatment for low-grade LE without dissemination was frequently 
EBRT, whereas the treatment for high-grade LE and disseminated lymphomas were 
more frequently chemotherapy. (Table 4) Current guidelines for treatment of high-grade 
lymphoma subtypes MCL and DLBCL and high-stage EMZL and FL with high tumor 
burden, are R-CHOP or R-CHOP ‘like’ chemotherapy.11-14 
 The rate of recurrences of LE was higher when compared to the conjunctiva: EMZL 
had a recurrence rate of 66% when occurring in the eyelid, whereas only 38% recurred 
when occurring in the conjunctiva.7 Likewise FL had a higher recurrence rate 
(conjunctiva, 43%7 versus eyelid, 60%). DLBCL had a high recurrence at both sites 
(conjunctiva, 67% versus eyelid, 78%). MCL had a particularly high rate of recurrence 
at both sites (conjunctiva, 81% versus eyelid, 100%). 
 The design of this study, being a retrospective database study, has some inherent 
limitations. The patients in the database were collected from 7 eye cancer centers and 
over a 30-year period. Thus, there were incomplete medical records and 
heterogeneous diagnostic methods used, which we minimized by reviewing the 
specimens according to the WHO classification.1 Further, the median follow-up was 
relatively short at 53 months, for some subtypes of lymphoma of indolent nature the 
duration of follow-up may not had been long enough to recognize the outcome 
variables. However, the multicenter database was large, which gives far greater and 
valuable information for a rare disease. 
 In a review study on LE,5 the number of T-cell LE is much higher than the number 
found in this study. This could be due to several factors. Firstly, a publishing bias with a 
higher rate of rare T-cell lymphomas and lower rate of indolent EMZL and FL could be 
present in the literature review. Secondly as the eyelid contains skin a higher proportion 
of cutaneous T-cell lymphomas15 like MF, LyP and C-ALCL is expected in the eyelid 
compared to other ocular adnexal sites. Some of the cutaneous T-cell lymphoma 
subtypes of the eyelid may have been examined and treated in non-ophthalmological 
centers and, thus, not included in our database. Further, MF often presents as a 
relapsed disease (Table 3) and therefore, a biopsy for histological examination from the 
eyelid may not have been carried out.  
 The ocular oncology center in Houston have a higher number of specific subtypes: 
MF as well as FL were more common. (Table 1) This could be due to a selection bias 
as some high-grade lymphoma patients are referred to specialized centers whilst low-
grade lymphoma patients tend to be treated locally in non-referral centers. 
 The eye cancer center in Copenhagen, Denmark had access to the national 
database of LE and, thus, a national distribution was available. The distribution of the 
lymphoma subtypes in the Danish center matches the entire group of LE in the present 
study. (Table 1) This indicates that the present study’s distribution of LE is also 
representative of the national distributions.  
 The main predictor of outcome was the histological lymphoma subtype: DLBCL and 
MCL had a poorer prognosis (5-year DSS, 21% and 50%, respectively) than FL and 
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EMZL (5-year DSS, 88% and 88%, respectively). (Figure 2) The T-cell lymphoma MF 
had a good prognosis with a 5-year DSS of 86%.(Figure 2) The finding that the 
histopathological subtype is a main predictor of outcome has also been found by Graue 
et al. for OAL.16 When comparing all LE, primary lymphoma (5-year DSS, 84%) had a 
significant (log rank test, p=0.038) better 5-year DSS than secondary LE (5-year DSS, 
64%). 
 The prognosis for LE has been considered worse than the prognosis of other 
OAL.6,17-20 However, compared to conjunctival lymphoma the prognosis of LE seems 
similar: 5-year DSS for EMZL (conjunctiva 97%7 versus eyelid 88%) and 5-year DSS 
for FL (conjunctiva 82%7 versus eyelid 88%). Only in DLBCL the 5-year DSS was 
worse (conjunctiva 55%7 versus eyelid 21%). In contrast the 5-year DSS for MCL of the 
eyelid was better than in the conjunctiva (conjunctiva 21%7 versus eyelid 50%). This 
novel information regarding outcome of the different subtypes of LE could be 
incorporated in the future AJCC staging system.
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Figure legends 
 
Figure 1. Clinical and histological findings of a secondary mantle cell lymphoma of the 
eyelid in a 51-year-old male. 
(Top left) Nodular tumor (arrow) presenting in the medial portion of the right upper 
eyelid. (Top right) Computed tomography showing a tumor mass (arrow) of the right 
upper eyelid and spreading to the nasal ridge. (Center left) The tumor shows diffuse 
infiltration of the tissue by small to medium sized lymphoid tumor cells (hematoxylin-
eosin, bar=50 µm). (Center right) The tumors cells demonstrates positivity for anti-Bcl-2 
(bar=50 µm). (Bottom left) Only a few tumor cells are positive for anti-CD3 (bar=50 µm). 
(Bottom right) The tumor cells are reacting with anti-cyclin D-1 (bar=50 µm). 
 
Figure 2. Disease-specific survival by subtype of lymphoma of the eyelid. 
(Left) Disease-specific survival is associated with the subtype of lymphoma of the 
eyelid. Low-grade subtypes like extranodal marginal zone lymphoma and follicular 
lymphoma have a more favorable prognosis than high-grade subtypes such as diffuse 
large B-cell lymphoma and mantle cell lymphoma. (Right) T-cell lymphomas of the 
eyelid seem to have a good prognosis; this is also the case for the most common T-cell 
lymphoma subtype of the eyelid mycosis fungoides. 
Abbreviations: ALCL, anaplastic large cell lymphoma; BCL, NOS, B-cell lymphoma, not 
otherwise specified; C-ALCL, primary cutaneous anaplastic large cell lymphoma; 
DLBCL, diffuse large B-cell lymphoma; EMZL, extranodal marginal zone lymphoma; FL, 
follicular lymphoma; LPL, lymphoplasmacytic lymphoma; LyP, lymphomatoid papulosis; 
MCL, mantle cell lymphoma; MF, mycosis fungoides; PTCL, peripheral T-cell 
lymphoma; SLL/CLL, small lymphocytic lymphoma; TCL, NOS, T-cell lymphoma, not 
otherwise specified. 
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Table 1. Eye Cancer Center Distribution of Patients by Subtype of Lymphoma of 
the Eyelid 
Eye Cancer Center 
 CPH LIV HOU HYD NY ATL MEL 
Subtype (n=22) (n=33) (n=22) (n=4) (n=3) (n=1) (n=1) 
B-CELL LYMPHOMAS 
EMZL        
  No. of Patients 9 18 3 0 1 0 1 
  Median age, y 69 62 61 NA 75 NA 55 
  Male to female ratio 3:6 5:13 1:2 NA 0:1 NA 1:0 
FL        
  No. of Patients 2 6 8 2 2 0 0 
  Median age, y 66 60 58 68 81 NA NA 
  Male to female ratio 2:0 1:5 5:3 2:0 2:0 NA NA 
DLBCL        
  No. of Patients 3 3 1 2 0 0 0 
  Median age, y 65 61 29 53 NA NA NA 
  Male to female ratio 2:1 2:1 0:1 1:1 NA NA NA 
MCL        
  No. of Patients 2 3 2 0 0 0 0 
  Median age, y 80 75 69 NA NA NA NA 
  Male to female ratio 2:0 2:1 1:1 NA NA NA NA 
LPL        
  No. of Patients 0 1 0 0 0 0 0 
  Median age, y NA 68 NA NA NA NA NA 
  Male to female ratio NA 0:1 NA NA NA NA NA 
SLL/CLL        
  No. of Patients 1 0 0 0 0 0 0 
  Median age, y 75 NA NA NA NA NA NA 
  Male to female ratio 1:0 NA NA NA NA NA NA 
BCL, NOS        
  No. of Patients 0 0 0 0 0 1 0 
  Median age, y NA NA NA NA NA 84 NA 
  Male to female ratio NA NA NA NA NA 0:1 NA 
T-CELL LYMPHOMAS 
MF        
  No. of Patients 1 0 7 0 0 0 0 
  Median age, y 77 NA 79 NA NA NA NA 
  Male to female ratio 1:0 NA 6:1 NA NA NA NA 
PTCL        
  No. of Patients 1 1 0 0 0 0 0 
  Median age, y 59 35 NA NA NA NA NA 
  Male to female ratio 1:0 1:0 NA NA NA NA NA 
LyP        
  No. of Patients 1 0 1 0 0 0 0 
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  Median age, y 34 NA 73 NA NA NA NA 
  Male to female ratio 1:0 NA 1:0 NA NA NA NA 
C-ALCL        
  No. of Patients 1 0 0 0 0 0 0 
  Median age, y 61 NA NA NA NA NA NA 
  Male to female ratio 1:0 NA NA NA NA NA NA 
ALCL        
  No. of Patients 1 0 0 0 0 0 0 
  Median age, y 54 NA NA NA NA NA NA 
  Male to female ratio 1:0 NA NA NA NA NA NA 
TCL, NOS        
  No. of Patients 0 1 0 0 0 0 0 
  Median age, y NA 48 NA NA NA NA NA 
  Male to female ratio NA 1:0 NA NA NA NA NA 
 
Table 1. Eye Cancer Center Distribution of Patients by Subtype of Lymphoma of 
the Eyelid 
Abbreviations: ALCL, anaplastic large cell lymphoma; ATL, Atlanta, Georgia, USA; 
BCL, NOS, B-cell lymphoma, not otherwise specified; C-ALCL, primary cutaneous 
anaplastic large cell lymphoma; CPH, Copenhagen, Denmark; DLBCL, diffuse large B-
cell lymphoma; EMZL, extranodal marginal zone lymphoma; FL, follicular lymphoma; 
HOU, Houston, Texas, USA; HYD, Hyderabad, India; LIV, Liverpool, England; LPL, 
lymphoplasmacytic lymphoma; LyP, lymphomatoid papulosis; MCL, mantle cell 
lymphoma; MEL, Melbourne, Australia; MF, mycosis fungoides; NA, not applicable; NY, 
New York, New York, USA; PTCL, peripheral T-cell lymphoma; SLL/CLL, small 
lymphocytic lymphoma; TCL, NOS, T-cell lymphoma, not otherwise specified. 
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Table 2. Location, Frequency of Symptoms, and Clinical Signs at Presentation of Lymphoma of the Eyelid 
 B-cell lymphomas, No. (%) patients T-cell lymphomas, No. (%) patients 
 EMZL FL DLBCL MCL LPL SLL BCL, NOS MF PTCL LyP 
C-
ALCL ALCL 
TCL, 
NOS 
 
32 
(37) 
20 
(23) 9 (10) 7 (8) 
1 
(1) 
1 
(1) 1 (1) 8 (9) 2 (2) 
2 
(2) 1 (1) 1 (1) 1 (1) 
Eyelida, b              
  Right 14 15 5 3 1 1 1 8 2 1  1 1 
  Left 23 8 1 6 1 1  8   1   
Symptomc              
  
Tumor/swelling 9 (28) 
13 
(65) 6 (67) 
4 
(57)  1  
1 
(13)  2 1 1  
  Epiphora  3 (15)      1 (13)      
  Irritation/pain 1 (3)  2 (22) 1 (14)    
1 
(13)      
  Diplopia 2 (6) 1 (5)  3 (43)        1  
  Ptosis 1 (3)   1 (14)  1  
1 
(13)      
  Erythema    1 (14)    
3 
(38)      
  Decreased VA 2 (6)             
  B symptoms 1 (3) 1 (5)  1 (14)    
1 
(13)      
  Not stated 22 (69) 6 (30) 3 (33) 
3 
(43) 1  1 
1 
(13) 2    1 
Signc              
  Mass 9 (28) 10 (50) 5 (56) 
4 
(57)  1  
1 
(13) 1 1 1 1  
  Epiphora  2 (10)            
  Diplopia 2 (6) 2 (10)  1        1  
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(14) 
  Ptosis  1 (5)         1   
  Ulceration        1 (13) 1 1 1   
  Chemosis  2 (10) 2 (22)     1 (13)      
  Edema 3 (9)  2 (22)      1     
  Ectropion        6 (63)      
  Not stated 20 (63) 6 (30) 3 (33) 
3 
(42) 1  1  1 1   1 
Local spreada              
  Orbit 6 6 4 4   1     1  
  Conjunctiva 2 5    1        
  Lacrimal sac 1 2            
  Lacrimal gland   2           
 
Table 2. Location, Frequency of Symptoms, and Clinical Signs at Presentation of Lymphoma of the 
Eyelid 
Abbreviations: ALCL, anaplastic large cell lymphoma; BCL, NOS, B-cell lymphoma, not otherwise specified; C-
ALCL, primary cutaneous anaplastic large cell lymphoma; DLBCL, diffuse large B-cell lymphoma; EMZL, 
extranodal marginal zone lymphoma; FL, follicular lymphoma; LPL, lymphoplasmacytic lymphoma; LyP, 
lymphomatoid papulosis; MCL, mantle cell lymphoma; MF, mycosis fungoides; PTCL, peripheral T-cell 
lymphoma; SLL, small lymphocytic lymphoma; TCL, NOS, T-cell lymphoma, not otherwise specified; VA, visual 
acuity. 
aNot specified for all cases. 
bA total of more than 100% because patients may have bilateral affection. 
cA total of more than 100% because patients may have 1 or more symptoms or signs. 
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Table 3. Clinical and Staging Characteristics of Patients by Subtype of Lymphoma of the Eyelida 
 B-CELL LYMPHOMAS, No. (%) patients T-CELL LYMPHOMAS, No. (%) patients 
 EMZL FL DLBCL MCL LPL SLL/CLL BCL, NOS MF PTCL LyP 
C-
ALCL ALCL 
TCL, 
NOS 
Characteristic (n=32) (n=20) (n=9) (n=7) (n=1) (n=1) (n=1) (n=8) (n=2) (n=2) (n=1) (n=1) (n=1) 
Sex              
  Male 10 (31) 
12 
(60) 5 (56) 
5 
(71) 0 1 0 
7 
(88) 2 2 1 1 1 
  Female 22 (69) 8 (40) 4 (44) 
2 
(29) 1 0 1 
1 
(13) 0 0 0 0 0 
Age at 
presentation, y              
  ≤60 14 (44) 
10 
(50) 4 (44) 0 0 0 0 
1 
(13) 2 1 0 1 1 
  >60 18 (56) 
10 
(50) 5 (56) 
7 
(100) 1 1 1 
7 
(88) 0 1 1 0 0 
Primary 
disease 
22 
(69) 
16 
(80) 4 (44) 
3 
(43) 1 0 0 
1 
(13) 1 2 1 0 0 
Disseminated 
disease 5 (16) 2 (10) 3 (33) 
3 
(43) 0 0 1 0 1 0 0 1 1 
Relapsed 
disease 5 (16) 2 (10) 2 (22) 
1 
(14) 0 1 0 
7 
(88) 0 0 0 0 0 
Laterality              
  Unilateral 24/31 (77) 
15 
(75) 9 (100) 
5 
(71) 0 0 1 0 2 2 1 1 1 
  Bilateral 7/31 (23) 5 (25) 0 
2 
(29) 1 1 0 
8 
(100) 0 0 0 0 0 
Ann Arbor 
stage              
  IE 24 (75) 
12 
(60) 3 (33) 
1 
(14) 0 0 0 
3 
(38) 1 2 1 0 0 
  IIE 2 (6) 3 (15) 2 (22) 2 (29) 1 0 0 
3 
(38) 1 0 0 0 0 
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  IIIE 2 (6) 0 2 (22) 1 (14) 0 0 0 0 0 0 0 1 1 
  IVE 4 (13) 5 (25) 2 (22) 3 (43) 0 1 1 
2 
(25) 0 0 0 0 0 
AJCC TNM 
stageb              
  T1 0 0 0 0 0 0 0 0 0 0 0 0 0 
  T2 0 0 0 0 0 0 0 0 0 0 0 0 0 
  T3 22/22 (100) 
16/16 
(100) 
4/4 
(100) 
3/3 
(100) 1 0 0 
1/1 
(100) 1/1 1/1 1 0 0 
  T4 0 0 0 0 0 0 0 0 0 0 0 0 0 
Recurrence              
  Yes 21 (66) 
12 
(60) 7 (78) 
7 
(100) 1 1 0 
3/7 
(43) 2 0 1 0 1 
  No 11 (34) 8 (40) 2 (22) 0 0 0 1 
4/7 
(57) 0 2 0 1 0 
Site of 
recurrence 
             
  OAR 7/21 (33) 
5/12 
(42) 
1/5 
(20) 
1/6 
(17) 0 1 0 0 0 0 1 0 0 
  OAR plus 
nodal and/or 
extranodal 
7/21 
(33) 
3/12 
(25) 
1/5 
(20) 
1/6 
(17) 0 0 0 0 0 0 0 0 0 
  Nodal and/or 
extranodal 
7/21 
(33) 
4/12 
(33) 
3/5 
(20) 
4/6 
(67) 1 0 0 
3/3 
(100) 2 0 0 0 1 
Disease status 
at last follow-
up 
             
  Complete 
remission 
15/31 
(48) 9 (45) 1 (11) 
2 
(29) 0 0 1 
2 
(25) 1 1 1 1 0 
  Alive with 
disease 
5/31 
(16) 5 (25) 0 
2 
(29) 0 0 0 
1 
(13) 1 0 0 0 0 
  Dead from 8/31 3 (15) 6 (67) 3 1 0 0 1 0 0 0 0 1 
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lymphoma (26) (43) (13) 
  Dead from 
other causes 
than lymphoma 
3/31 
(10) 3 (15) 2 (22) 0 0 1 0 
4 
(50) 0 1 0 0 0 
Table 3. Clinical and Staging Characteristics of Patients by Subtype of Lymphoma of the Eyelid 
Abbreviations: AJCC, American Joint Committee on Cancer; ALCL, anaplastic large cell lymphoma; BCL, NOS, B-cell 
lymphoma, not otherwise specified; C-ALCL, primary cutaneous anaplastic large cell lymphoma; DLBCL, diffuse large B-
cell lymphoma; EMZL, extranodal marginal zone lymphoma; FL, follicular lymphoma; LPL, lymphoplasmacytic lymphoma; 
LyP, lymphomatoid papulosis; MCL, mantle cell lymphoma; MF, mycosis fungoides; OAR, ocular adnexal region; PTCL, 
peripheral T-cell lymphoma; SLL/CLL, small lymphocytic lymphoma; TCL, NOS, T-cell lymphoma, not otherwise specified. 
aData are not specified for all patients. 
bOnly primary lymphoma of the eyelid were staged according to the AJCC staging system. 
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Table 4. Management of Patients by Subtype and Stage of Lymphoma of the Eyelida 
 No. (%) 
patients 
 
     
Stage EBRT EBRT plus CTX CTX 
CTX plus 
Rituximab 
EBRT and CTX plus 
Rituximab Rituximab Surgery 
B-CELL LYMPHOMAS 
EMZL        
  IE or IIE 13 (46) 7 (25) 0 0 1 (4) 0 7 (25) 
  IIIE or 
IVE 0 2 (40) 2 (40) 0 0 1 (20) 0 
FLb        
  IE or IIE 4 (24) 4 (24) 3 (18) 1 (6) 2 (12) 1 (6) 2 (12) 
  IVE 0 1 (20) 2 (40) 1 (20) 1 (20) 0 0 
DLBCL        
  IE or IIE 0 4 (80) 1 (20) 0 0 0 0 
  IIIE or 
IVE 0 2 (50) 1 (25) 0 1 (25) 0 0 
MCL       
  IE or IIE 0 3 (60) 1 (20) 0 0 0 1 (20) 
  IIIE or 
IVE 0 1 (25) 0 2 (50) 1 (25) 0 0 
LPLc        
  IIE 0 1 0 0 0 0 0 
SLL/CLLd        
  IVE 0 0 1 0 0 0 1 
T-CELL LYMPHOMAS 
MF        
  IE or IIE 1 (25) 2 (50) 1 (25) 0 0 0 0 
  IIIE or 
IVE 0 2 (100) 0 0 0 0 0 
PTCLe        
  IE or IIE 0 1 0 0 0 0 1 
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LyPf        
  IE 0 0 0 0 0 0 1 
C-ALCLf        
  IE 0 1 0 0 0 0 0 
ALCLg        
  IIIE 0 0 1 0 0 0 0 
TCL, 
NOSg        
  IIIE 0 1 0 0 0 0 0 
 
Table 4. Management of Patients by Subtype and Stage of Lymphoma of the Eyelid  
Abbreviations: ALCL, anaplastic large cell lymphoma; C-ALCL, primary cutaneous anaplastic large cell lymphoma; CTX, 
chemotherapy; DLBCL, diffuse large B-cell lymphoma; EBRT, external beam radiation therapy; EMZL, extranodal 
marginal zone lymphoma; FL, follicular lymphoma; LPL, lymphoplasmacytic lymphoma; LyP, lymphomatoid papulosis; 
MCL, mantle cell lymphoma; MF, mycosis fungoides; PTCL, peripheral T-cell lymphoma; SLL/CLL, small lymphocytic 
lymphoma; TCL, NOS, T-cell lymphoma, not otherwise specified. 
aData are not specified for all patients. All percentages are row percentages. No data was available for the BCL, NOS. 
bNone of the cases of FL were stage IIIE. 
cThe case of LPL was stage IIE. 
dThe case of SLL/CLL was stage IVE. 
eThe 2 cases of PTCL were stage IE and IIE. 
fBoth cases of LyP and the case of C-ALCL were stage IE. 
gThe cases of ALCL and TCL, NOS were stage IIIE. 
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